Literature DB >> 11071626

The molecular biology of chronic myeloid leukemia.

M W Deininger1, J M Goldman, J V Melo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11071626

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  352 in total

Review 1.  Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

Review 2.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

3.  Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Authors:  Fang Zheng; Huiyu Li; Kaiwei Liang; Yimei Du; Dongmei Guo; Shiang Huang
Journal:  Med Oncol       Date:  2011-12-10       Impact factor: 3.064

4.  MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.

Authors:  Sukanya Suresh; Lynn McCallum; Wanhua Lu; Noureddine Lazar; Bernard Perbal; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2011-06-03       Impact factor: 5.782

5.  Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.

Authors:  Yuka Hirose; Hitoshi Kiyoi; Masanori Iwai; Toshiya Yokozawa; Masafumi Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

6.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

7.  Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.

Authors:  Oliver Hantschel
Journal:  Haematologica       Date:  2012-02       Impact factor: 9.941

8.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

9.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

10.  Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Authors:  Manabu Kurokawa; Takahiro Ito; Chih-Sheng Yang; Chen Zhao; Andrew N Macintyre; David A Rizzieri; Jeffrey C Rathmell; Michael W Deininger; Tannishtha Reya; Sally Kornbluth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-16       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.